jeudi 6 septembre 2018

Onco Actu du 6 septembre 2018

4.1 Dép., diag. & prono. - Prostate

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline [BMJ]

4.2 Dép., diag. & prono. - Génome

23andMe is gauging interest in a $749 'premium' service that would offer deeper health data [CNBC]

5. Traitements

Discovering better treatments for children with brain tumours [Cancer Research UK]

Hormone Therapy Can Make Prostate Cancer Worse, Study Finds [Cedars-Sinai]

5.1 Traitements - Pré-clinique

Scientists identify weak point in deadly eye melanoma [WUSTL]

Path to a targeted treatment for small-cell lung cancer? [Fred Hutch]

5.10 Traitements - Essais

Strata Oncology Announces Participation in the NCI-MATCH Clinical Trial [Strata]

With big-name backing, a startup launches to match cancer patients with clinical trials [STAT]

5.12.1 Immunothérapies - partenariats

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca [Biothera]

Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate Combination Therapy with CMP‐001 and Avelumab [Checkmate Pharma]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

After snubbing Gilead, British cost watchdogs give thumbs-up to Novartis’ CAR-T Kymriah [FiercePharma]

NHS England to fund personalised blood cancer immunotherapy [Cancer Research UK]

UK deal makes Novartis cancer cell therapy available to kids [Reuters]

5.12.5 Immunothérapies - Pharma

FDA extends review of Roche's Tecentriq by three months [Reuters]

5.12.8 Immunothérapies - Economie

Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths [FiercePharma]

5.13 WCLC

Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) [Roche]

5.2 Pharma

Agios crowns Celgene veteran Jackie Fouse CEO to spearhead leukemia drug launches [FiercePharma]

Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 [Loxo Oncology]

FDA waves Loxo through for second ‘breakthrough’ in tissue-agnostic cancer therapy [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s global efforts to help assure product quality and transparency at foreign drug manufacturing facilities [FDA]

5.3.4 Traitements - AMM (FDA, EMA,...)

Eli Lilly, Chi-Med’s Elunate becomes first China-made cancer drug to win a key nod [FiercePharma]

Eisai and Merck Announce China National Medical Products Administration (NMPA) Approval of LENVIMA® (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma (HCC) [Merck]

6.11 Patients

Not if but when: After a diagnosis of brain cancer, a young dad and his family grapple with the uncertain time he has left [STAT]

6.12 Ethique

All study participants have a right to know their own results. My lab has been doing that for years [STAT]

6.6 Publications

AACR Apologizes for Delays in Retracting Papers [The Scientist]

Documentary puts lens on the open-access movement upending scientific publishing [Science]